Clarivate Sells Life Sciences Unit to Altaris for $600M

Clarivate (ticker: CLVT) is making a major strategic move by selling off its Life Sciences & Healthcare business to Altaris, a private equity firm that specializes in healthcare investments, for $600 million. If you've never heard of Clarivate, think of them as the company behind some of the world's most well-known data and analytics tools used by researchers, academics, and yes — life sciences professionals.

Divestitures like this one are pretty common when a company decides it wants to sharpen its focus. By parting ways with its Life Sciences & Healthcare unit, Clarivate is essentially saying, "This division would be better off somewhere else, and we'd rather concentrate on what we do best." For Altaris, which already has deep roots in healthcare-focused investing, picking up this unit is a natural fit — it's the kind of acquisition that makes strategic sense on both sides of the table.

Read more Bausch Health Canada Adds PrOKEDI Doses to Quebec Drug List →

The $600 million price tag is no small figure, and the proceeds could give Clarivate some financial breathing room — whether that means paying down debt, buying back shares, or reinvesting in its core businesses. That part is worth watching closely if you're a CLVT shareholder or someone keeping tabs on the data analytics sector.

Deals of this scale tend to signal broader shifts in how companies are rethinking their portfolios in a higher-interest-rate environment, where investors are increasingly rewarding businesses that stay in their lane rather than sprawling across multiple industries. Clarivate's move fits squarely into that trend.

Continue reading at Yahoo Finance